SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-014080
Filing Date
2019-03-12
Accepted
2019-03-12 07:29:55
Documents
3
Period of Report
2019-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a19-6279_18k.htm 8-K 22204
2 EX-99.1 a19-6279_1ex99d1.htm EX-99.1 140781
3 GRAPHIC g62791mm01i001.jpg GRAPHIC 3568
  Complete submission text file 0001104659-19-014080.txt   169272
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 19673941
SIC: 2834 Pharmaceutical Preparations